← Back to Home

Neurosterix raises $105 million to advance M4 schizophrenia drug into Phase 2 development

New funding moves an oral candidate that modulates signaling in the brain toward its next stage. NTX-253 has completed Phase 1 trials, but whether it can improve symptoms and reduce the treatment burden remains to be answered in patient trials.

By SURL BioNews

Treating schizophrenia requires not only controlling psychotic symptoms but also considering the physical burden of medication. Neurosterix, which is targeting a different signaling pathway in the brain, has now secured funding to advance clinical development: Addex Therapeutics announced on November 11 that the spinout company had completed a $105 million Series B financing, primarily to fund Phase 2 development of its oral candidate NTX-253.

The Addex announcement and the same document filed with the U.S. Securities and Exchange Commission (SEC) stated that NTX-253 had completed single- and multiple-ascending-dose Phase 1 trials. RTTNews also confirmed in its report the following day that the funding would support subsequent Phase 2 testing. However, the disclosures describe development plans and do not provide information indicating that Phase 2 enrollment has begun.

NTX-253 targets the muscarinic acetylcholine M4 receptor and is a positive allosteric modulator (PAM). These drugs enhance a receptor’s response to signals by acting at a site distinct from where the natural signaling molecule binds. According to the company, the development rationale is to indirectly modulate dopamine signaling through the M4 pathway in pursuit of reducing psychotic symptoms.

The appeal of this pathway also lies in whether it can reduce movement disorders and metabolic problems associated with traditional dopamine antagonists. But this remains a development goal for NTX-253, rather than a demonstrated clinical advantage. Receptor selectivity and mechanism of action provide a rationale for research; these properties alone cannot establish efficacy or side effects in patients.

The limitations of the information publicly available at this stage are particularly important. The company said Phase 1 data support moving into larger trials, but this announcement did not list participant numbers, doses, adverse events or full results, nor did it specify the size, primary endpoints or timeline of Phase 2. Completing Phase 1 therefore marks a development milestone, but is not enough to determine therapeutic efficacy or long-term safety.

The new funding will also support Neurosterix’s other neuropsychiatric programs, including NTX-819, an mGlu7 negative allosteric modulator for mood and anxiety disorders, and another M4 candidate, NTX-529. Addex did not participate in this financing round and holds an 8.5% stake following the financing. The company disclosed that the stake was valued at approximately $18.6 million; this is an equity value, rather than cash proceeds received by Addex in this financing.

For NTX-253, the most direct significance of this financing is that it provides resources for the next stage of clinical validation. The central questions will now return to patients: how much symptom improvement can modulation of signaling through M4 deliver, and what risks will it entail? Answers will need to be established gradually through clearly designed trials and complete results.

References

  1. Addex Therapeutics
  2. Addex Therapeutics via SEC EDGAR
  3. RTTNews